MSD’s Deal Puts Spotlight on hVIVO’s Role in Next-Generation Flu Protection
Merck Sharp & Dohme (MSD) has agreed to acquire Cidara Therapeutics in a transaction valued at approximately $9.2 billion, in a move that underscores the growing strategic importance of long-acting antivirals – and of specialist partners such as hVIVO plc.
The deal follows encouraging phase 2b results for Cidara’s lead antiviral candidate, CD388, and highlights how collaborative clinical development can translate into major value creation in the infectious disease space.
CD388 is a long-acting, strain-agnostic antiviral agent designed to prevent influenza infection in people at higher risk of serious complications. Unlike traditional approaches that are often strain-specific, CD388 offers protection against both influenza A and influenza B, aiming to provide broader and more durable coverage across multiple flu seasons.
The candidate has already attracted significant regulatory interest, securing both Breakthrough Therapy and Fast Track Designations from the US Food and Drug Administration. It is now progressing through phase III clinical development, positioning it as a potential first-in-class option in preventative influenza care.
hVIVO has been closely embedded in CD388’s journey from early proof of concept through to large-scale field evaluation. In 2023, the company conducted a randomised, double-blind influenza human challenge study, a specialist model in which healthy volunteers are deliberately exposed to influenza under controlled conditions.
The trial enrolled 59 participants and produced compelling data: those treated with CD388 demonstrated reduced viral loads compared with placebo, offering early evidence that the drug could meaningfully blunt the impact of infection.
On the back of these results, Cidara advanced CD388 into a phase IIb field study during the 2024/2025 flu season, with hVIVO selected as the only United Kingdom site. The company’s ability to recruit efficiently was put to the test – and passed with distinction.
hVIVO screened more than 1,100 participants and successfully dosed 817 of them within just six weeks, achieving the highest recruitment numbers of any site globally. The phase IIb trial went on to meet all primary and secondary endpoints, reinforcing CD388’s potential as a breakthrough therapy for high-risk populations.
Beyond its work on the front line of recruitment and clinical delivery, hVIVO has also served as the central virology laboratory for both the phase 2b and phase 3 programmes. This role has spanned consultancy, global sample logistics management and the execution of key virology and immunology assays.
By integrating scientific expertise with operational execution, hVIVO has helped ensure that complex, multi-centre studies could run smoothly while generating robust, regulatory-grade data.
The Chief Executive Officer of hVIVO said that the company congratulates Cidara on this landmark transaction with MSD, noting that it represents a major milestone for the infectious disease sector.
For hVIVO, the CEO emphasised that the deal demonstrates how human challenge trial expertise can lead directly to significant downstream value creation. It also serves as a validation of hVIVO’s deliberate strategy to diversify beyond challenge studies into field trials and standalone laboratory services.
According to the CEO, this evolution has been made possible by the company’s highly efficient patient recruitment and site services, underpinned by extensive infectious disease knowledge and capabilities.
Final Thoughts
As MSD moves to bring Cidara and CD388 into its portfolio, the transaction reflects a broader shift in how pharmaceutical innovation is being delivered – with specialised partners playing a central role from early-stage modelling through to late-stage development.
For hVIVO, the acquisition is more than a headline-grabbing deal; it is a tangible endorsement of its integrated model, combining human challenge trials, field study operations and central lab expertise.
In an era where influenza and other respiratory threats remain a persistent global concern, the CD388 story illustrates how targeted collaboration, scientific rigour and operational excellence can converge to accelerate promising therapies from the lab bench towards real-world impact.
News Credit: MSD to acquire Cidara after positive phase 2b trial results
Things you may also like: